Four years after Frank Fan left Legend — a company he co-founded — he's back at ASCO with new CAR-T company Wondercel Therapeutics.
In 2022, Frank Fan moved more than 800 miles from Nanjing to Shenzhen, China, seeking a fresh start. He had abruptly left Legend Biotech, the …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
ASCO 2026: Mixed SCLC result for Legend’s LB2102, Novartis expedites manufacture - Pharmaceutical Technology
Fierce Pharma Asia—More China biotech hawkishness; Pfizer’s $10B Innovent deal; Astellas’ roadmap
Allogene CEO to step down; Agios drug fails key test
A turning point for pancreatic cancer patients
Feng, whose work focuses on liver cancer and immunotherapy, will lead research institute at Shenzhen Bay Laboratory after 40…
Legend Biotech’s long-awaited first showing of in vivo CAR-T data is here, fueling momentum in the growing field.
In 2017, a little-known company called Nanjing Legend Biotech walked into the ASCO annual meeting at the 11th hour, dropped a…
As Legend’s LB2102 trial in SCLC fails to dazzle, co-developer Novartis banks on quick manufacturing to find a commercial edge.
New York City-based startup Waypoint Bio has raised $20 million in series A financing to test multiple cell therapies in China.
Longtime Allogene CEO David Chang will be stepping down at the end of June. Chang has served as the company’s CEO for the past…
